Your session is about to expire
← Back to Search
Captopril for Myeloproliferative Neoplasms
Study Summary
This trial is testing if captopril is safe and effective for treating people with myelofibrosis by reducing the grade of bone marrow scar tissue.
- Myeloproliferative Neoplasms
- Bone Marrow Fibrosis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2009 Phase 4 trial • 252 Patients • NCT00391846Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had radiation therapy to your spleen within the last 3 months before starting captopril.You are currently taking part in another study with experimental drugs.
- Group 1: Captopril
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the overall participant count for this experiment?
"At this juncture, the study is not taking on additional patients. The medical trial was first uploaded in December 1st 2022 and last revised August 16th 2022. If you are searching for other trials, 2906 studies related to fibrosis are currently recruiting while 6 trials regarding Captopril still need participants."
What medical conditions does Captopril most frequently serve to alleviate?
"Captopril has been observed to address the symptoms of ventricular dysfunction, left-sided heart failure, and diabetic nephropathy."
Are there still opportunities for individuals to contribute to this research?
"The information listed on clinicaltrials.gov indicates that the recruitment process for this trial has been concluded, as of August 16th 2022. However, there are still 2912 other trials actively seeking applicants at present."
Share this study with friends
Copy Link
Messenger